Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma

BACKGROUND & AIMS: Infigratinib is a pan‐FGFR (fibroblast growth factor receptor) inhibitor that has shown encouraging activity in FGFR‐dependent hepatocellular carcinoma (HCC) models. However, long‐term treatment results in the emergence of resistant colonies. We sought to understand the mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Prawira, Aldo, Le, Thi Bich Uyen, Vu, Thanh Chung, Huynh, Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Liver Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894323/
https://www.ncbi.nlm.nih.gov/pubmed/33179425
http://dx.doi.org/10.1111/liv.14728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894323/
https://www.ncbi.nlm.nih.gov/pubmed/33179425
http://dx.doi.org/10.1111/liv.14728

Ejemplares similares